Israel-based BioLight Life Sciences has reported positive results from a feasibility clinical study of its CellDetect technology in detecting prostate cancer cells in urine samples.
Developed by BioLight's cancer diagnostics subsidiary, Micromedic Technologies, the CellDetect technology enables a non-invasive detection of cancerous and precancerous cells with accuracy using its patented kit comprised of unique extract and dyes offering a combination of colour and morphology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The feasibility study was carried out in the Kaplan Medical Center in Israel, where urine samples derived from prostate cancer patients and healthy patients were analysed using the CellDetect technology.
Out of 18 samples, Micromedic's research team was able to correctly diagnose each of the cases.
Assessment of the same by an external reviewer has also resulted in the correct identification of most cases of prostate cancer, as well as of the healthy subjects.
The results of the study validated the ability of the CellDetect technology to identify intact cells occurring in the prostate from urine samples following prostate massage.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBioLight CEO Susana Nahum Zilberberg said: "We are very pleased with the results from this clinical study, which validates the potential we see in the CellDetect technology to dramatically improve prostate cancer diagnostics.
"While prostate cancer is the second most common cancer in men worldwide, the currently available diagnostic testing is known to be unreliable or invasive and expensive.
“With the results that we have announced today, we are confident that CellDetect has the potential to transform prostate cancer diagnostics, offering patients a non-invasive, accurate and reliable test, and one that could improve the healthcare system through considerable cost savings."
A blinded, multi-centre clinical study of CellDetect conducted last year, had achieved its primary endpoint which was determining its efficacy in identifying the recurrence of bladder cancer in subjects who earlier had suffered the disease.
